|
π
|
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
20 auth.
W. Hueber,
B. Sands,
S. Lewitzky,
M. Vandemeulebroecke,
W. Reinisch,
P. Higgins,
J. Wehkamp,
B. Feagan,
M. Yao,
M. Karczewski,
...
J. Karczewski,
N. Pezous,
S. Bek,
G. Bruin,
Bjoern Mellgard,
C. Berger,
M. Londei,
A. Bertolino,
G. Tougas,
S. Travis
|
10 |
2012 |
10
π
|
|
π
|
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
22 auth.
W. Hueber,
D. Patel,
T. Dryja,
A. Wright,
I. Koroleva,
G. Bruin,
C. Antoni,
Z. Draelos,
M. Gold,
P. Durez,
...
P. Tak,
J. GΓ³mez-Reino,
Stephen Foster,
R. Y. Kim,
C. Samson,
N. Falk,
D. Chu,
D. Callanan,
Q. Nguyen,
Kristine L. Rose,
A. Haider,
F. D. Padova
|
9 |
2010 |
9
π
|
|
π
|
&bgr;βDefensin 2 is a responsive biomarker of ILβ17Aβdriven skin pathology in patients with psoriasis
16 auth.
F. Kolbinger,
C. Loesche,
M. Valentin,
Xiaoyu Jiang,
Yi Cheng,
P. Jarvis,
T. Peters,
C. Calonder,
G. Bruin,
F. Polus,
...
B. Aigner,
David M. Lee,
M. Bodenlenz,
F. Sinner,
T. Pieber,
D. Patel
|
7 |
2017 |
7
π
|
|
π
|
The human anti-IL-1Ξ² monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
15 auth.
R. Alten,
H. Gram,
L. Joosten,
W. B. Berg,
J. Sieper,
Siegfrid Wassenberg,
G. Burmester,
P. V. van Riel,
Maria Diaz-Lorente,
G. Bruin,
...
T. Woodworth,
C. Rordorf,
Yannik Batard,
A. Wright,
T. Jung
|
7 |
2008 |
7
π
|
|
π¦
|
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
G. Bruin,
C. Loesche,
J. Nyirady,
Oliver Sander
|
5 |
2017 |
5
π¦
|
|
π’
|
Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion
14 auth.
C. Dragatin,
F. Polus,
M. Bodenlenz,
C. Calonder,
B. Aigner,
K. Tiffner,
J. Mader,
M. Ratzer,
R. Woessner,
T. Pieber,
...
Yi Cheng,
C. Loesche,
F. Sinner,
G. Bruin
|
5 |
2016 |
5
π’
|
|
π
|
ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
10 auth.
M. R. John,
L. Widler,
R. Gamse,
T. Buhl,
K. Seuwen,
W. Breitenstein,
...
G. Bruin,
R. Belleli,
L. Klickstein,
M. Kneissel
|
5 |
2011 |
5
π
|
|
π
|
AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.
11 auth.
M. R. John,
Evita Harfst,
J. Loeffler,
R. Belleli,
J. Mason,
G. Bruin,
...
K. Seuwen,
L. Klickstein,
L. Mindeholm,
L. Widler,
M. Kneissel
|
5 |
2014 |
5
π
|
|
π
|
The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers
9 auth.
A. Kirsten,
H. Watz,
F. Pedersen,
O. Holz,
Rachel Smith,
G. Bruin,
...
S. Koehne-Voss,
H. Magnussen,
D. Waltz
|
5 |
2013 |
5
π
|
|
π
|
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *
13 auth.
M. Augustin,
K. Reich,
P. Yamauchi,
A. Pinter,
J. Bagel,
S. Dahale,
R. You,
G. Bruin,
Jimena Djimopoulos,
B. Paguet,
...
P. Charef,
M. Patekar,
D. Keefe
|
4 |
2022 |
4
π
|
|
π’
|
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
16 auth.
F. Kolbinger,
F. D. Di Padova,
A. Deodhar,
J. Hawkes,
C. Huppertz,
Torsten Kuiper,
I. McInnes,
C. Ritchlin,
D. Rosmarin,
G. Schett,
...
J. Carballido,
P. HΓ€usermann,
C. Calonder,
B. Vogel,
J. Rondeau,
G. Bruin
|
4 |
2021 |
4
π’
|
